The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia

Matteo Allegretti1,*, Maria Rosaria Ricciardi2,*, Roberto Licchetta1, Simone Mirabili1, Stefania Orecchioni3, Francesca Reggiani1, Giovanna Talarico1, Roberto Foà1, Francesco Bertolini3, Sergio Amadore4, Maria Rosaria Torrisi2 & Agostino Tafuri2

Aberrant activation of the PI3K/Akt/mTOR pathway is a common feature of acute myeloid leukemia (AML) patients contributing to chemoresistance, disease progression and unfavourable outcome. Therefore, inhibition of this pathway may represent a potential therapeutic approach in AML. The aim of this study was to evaluate the pre-clinical activity of NVP-BKM120 (BKM120), a selective pan-class I PI3K inhibitor, on AML cell lines and primary samples. Our results demonstrate that BKM120 abrogates the activity of the PI3K/Akt/mTOR signaling, promoting cell growth arrest and significant apoptosis in a dose- and time-dependent manner in AML cells but not in the normal counterpart. BKM120-induced cytotoxicity is associated with a profound modulation of metabolic behaviour in both cell lines and primary samples. In addition, BKM120 synergizes with the glycolytic inhibitor dichloroacetate enhancing apoptosis induction at lower doses. Finally, in vivo administration of BKM120 to a xenotransplant mouse model of AML significantly inhibited leukemia progression and improved the overall survival of treated mice. Taken together, our findings indicate that BKM120, alone or in combination with other drugs, has a significant anti-leukemic activity supporting its clinical development as a novel therapeutic agent in AML.

Over the last few decades, the prognosis for acute myeloid leukemia (AML) patients has shown no significant improvement and the frequency of relapse still remains very high with only 20–30% survival at 5 years1. Therefore, major efforts are being made to develop new therapeutic approaches targeting the aberrant signaling networks that sustain leukemia cell proliferation, survival and drug resistance2–5.

Phosphoinositide 3-kinases (PI3Ks) are a family of lipid enzymes divided into three classes (I–III) each with its own substrate specificity, structures and lipid products6–8. Class I PI3Ks are heterodimers composed of a p110 catalytic subunit (α, β, γ or δ) and a p85/p55/p50 regulatory subunit which are activated via tyrosine kinase or G protein-coupled receptors. Upon activation, cytosolic PI3K is recruited to the plasma membrane where it converts the lipid phosphatidylinositol bisphosphate (PIP2) to phosphatidylinositol trisphosphate (PIP3) inducing the colocalization of Akt and the phosphoinositide-dependent kinase 1 (PDK1) by their pleckstrin homology domain. Akt is then activated by PDK1 and mammalian target of rapamycin (mTOR) complex 2 (mTORC2) through two distinct phosphorylation on T308 and S473, respectively9,10. mTOR belongs to the PI3K-related kinase family and exists as two complexes, mTORC1 and mTORC2, which cooperate with Akt to control cell growth and proliferation, metabolism, transcription, protein translation and survival10,11. Given the pleiotropic functions, PI3Ks activity is...
tightly controlled and negatively regulated in normal cells by phosphatase and tensin homologue (PTEN) and SHIP-1/2, which dephosphorylates PIP3 in PIP2, inhibiting signaling transduction.

Deregulation of the PI3K/Akt/mTOR pathway is widely observed in human cancers8,12,13 and is approximately detected in 50–80% of the AML patients14–17. Over the last few years, constitutive activation of this axis in AML has been associated with poor prognosis and chemoresistance14,16,18. Moreover, it has been demonstrated that AML blasts heterogeneously expressed all class-I PI3K isoforms which are responsible for Akt activation, contributing to survival and proliferation of leukemic cells4. Therefore, a wide number of small molecules that target the PI3K/Akt/ mTOR signaling at multiple levels, alone or in combination with chemotherapeutic drugs, has been investigated showing potential therapeutic efficacy in AML19–21.

NVP-BKM120 (cited hereafter as BKM120) is a highly selective pan-class I PI3K inhibitor that binds to wild type or mutated p110 catalytic subunits, thus preventing ATP bound to the active site of PI3K22–24. Several reports have demonstrated that BKM120 exerts anti-proliferative and cytotoxic effects on solid tumor25–30 and hematological malignancies31–35 through the selective inhibition of Akt activity. Interestingly, BKM120 at micromolar range also affects the mTOR activity by downregulating the levels of S6 protein kinase (p70S6K) and eIF4EBP1, two well-known mTORC1 substrates27–29,36. Furthermore, it has been documented that BKM120 synergizes with well established chemotherapeutic drugs or other small molecules (i.e. mTOR or MEK inhibitors) to enhance apoptosis in vitro and in vivo27,28.

Here, we investigated the activity of BKM120 on human AML. Our results demonstrate that this drug inhibits cell proliferation and induces apoptosis on AML models and primary blasts by the selective inhibition of the PI3K/ Akt/mTOR pathway activity, while not affecting normal cells. A profound modulation of the AML metabolic phenotype is associated with BKM120-induced cytotoxicity. Moreover, BKM120 strongly synergizes with the glycolic modulator dichloroacetate (DCA), triggering apoptosis at lower doses in both AML cell lines and primary samples. Finally, BKM120 shows in vivo effectiveness prolonging the survival of an AML xenotransplant mouse model. Taken together, our findings demonstrate for the first time to our knowledge the efficacy of BKM120 as a novel therapeutic agent for AML.

**Results**

**PI3K/Akt/mTOR signaling activation on AML cell lines and primary samples.** The basal expression and phosphorylation levels of critical PI3K/Akt/mTOR pathway components were first evaluated by western blot analysis on AML cell lines. Our results show that AML cell lines constitutively expressed p-Akt(S473 and T308) and p-Gsk3α/β(S21 and S9) in a heterogeneously manner, thus suggesting different levels of PI3K addiction. Moreover, a constitutive activation of the mTOR signaling was observed, as documented by the overexpression of p-mTOR(S2448 and S2481), p-p70S6K(S371) and p-4EBP1(T37/46), readouts of the mTORC1 and mTORC2 activities, respectively (Fig. 1A). The PI3K/Akt/mTOR activation status of primary samples included in this study was then assessed with respect to cell availability. We found that 7/9 (77.8%) of tested samples were characterized by a higher phospho/total Akt ratio (mean 2.88 ± 2.4; range 0.12–7.93) than normal MNCs (1.00) and displayed p-mTOR(S2448 and S2481) and p-4EBP1 overexpression in comparison to normal cells, thus indicating the aberrant activation of the PI3K/Akt/mTOR axis in these cases (Fig. 1B).
BKM120 inhibits the PI3K/Akt/mTOR signaling in AML cell lines. To assess whether BKM120 was able to inhibit the PI3K pathway, AML cell lines (U-937, OCI-AML2, HL-60, OCI-AML3, MOLM-13 and KG-1) were cultured for 24 h with increasing doses of BKM120 and protein lysates were obtained at 3 and 24 h. A concentration of 2 μM was not exceeded to avoid off-target effects. Densitometric analysis revealed that BKM120 induced, both at 3 and 24 h, a clear dose-dependent reduction of the phospho/total Akt ratio in all cell lines tested, although with different degree. Akt dephosphorylation was associated with the downregulation of p-Gsk3α/β(S21/9) levels, suggesting the abrogation of the PI3K downstream activity. Moreover, at the higher doses, BKM120 also decreased the phosphorylation levels of mTOR on S2448 and on S2481, thus affecting both the mTORC1 and mTORC2 activity, and led to the downregulation of p-p70S6K(S371) and p-4EBP1(T37/46). No changes were detected on total proteins (Fig. 2 and Supplementary Fig. S1). Thus, these findings further support the selective inhibition of the PI3K/Akt/mTOR signaling promoted by BKM120.

BKM120 exerts anti-proliferative and pro-apoptotic effects on AML cell lines. To evaluate whether PI3K inhibition resulted into cell death, AML cell lines were cultured up to 72 h with increasing concentrations of BKM120 or DMSO. Cell viability and apoptosis induction were assessed by Trypan Blue exclusion and AnnV/PI staining, respectively. BKM120 exhibited dose- and time-dependent anti-proliferative and pro-apoptotic effects on all cell lines, irrespective of their PI3K activation status, showing IC₅₀ values between 0.7 and 1.2 μM (Supplementary Table S1). On the most sensitive cell line, U-937, a 24 h exposure resulted in a profound cell growth reduction and in a significant (p < 0.001) increase of AnnV/PI positive cells from 6.5% ± 0.1 (DMSO) to 91.7% ± 0.1 with 2 μM BKM120. Conversely, on the less sensitive cell line KG-1, apoptotic cells reached only 59.2% ± 0.1 (p < 0.001) after 72 h of 2 μM BKM120, still in the presence of a significant (p < 0.001) inhibition of cell growth at lower doses (Fig. 3). BKM120 cytotoxicity was preceded by a temporary G2/M block that was rapidly followed by induction of apoptosis, as demonstrated by the increase of the subG₀/G₁ peak at later times of treatment (data not shown). Together, these data confirmed the ability of BKM120 to impair cell cycle progression and mitosis regulation which ultimately turn into apoptosis.

BKM120 affects the PI3K/Akt/mTOR activity triggering apoptosis in primary AML samples. To evaluate the effectiveness of BKM120 as a potential therapeutic agent in AML, we investigated whether drug
treatment could downregulate the PI3K activity and induce apoptosis on primary AML samples. AML blasts (n = 15) from BM or PB were treated up to 144 h with increasing concentration of BKM120. Cell viability and apoptosis induction were evaluated by Trypan Blue exclusion and AnnV/PI staining, respectively. Protein lysates, according to cell availability, were obtained after 24 h of exposure from 3 AML samples. BKM120 treatment decreased blast counts in all de novo samples analyzed, triggering at 144 h an increase of AnnV positive cells from 20.1 ± 8.9% (DMSO) to 45.4 ± 19.1% (p < 0.001) at 2 μM (Fig. 4A and Supplemental Fig. 2). Of note, BKM120 proved its efficacy also on the two chemo-resistant AML samples (#4 and #18) (Fig. 4B). Western blot analysis on 3 out 3 primary specimens confirmed that BKM120 dose-dependently inhibited the PI3K/mTOR activity also on primary blasts, as demonstrated by the downregulation of p-Akt(S473) and p-4EBP1(T37/46) (Fig. 4C). Finally, BKM120 was tested on resting and phytohaemagglutinin (PHA)-activated MNCs isolated from 5 healthy volunteers failing to show considerable induction of apoptosis (Supplementary Fig. S3).

BKM120 modulates the metabolic phenotype of AML cells. Given the role of the PI3K/Akt/mTOR pathway in the regulation of cell metabolism, we asked whether BKM120 could modulate the metabolic phenotype of AML cell lines and primary samples. AML cell lines, U-937 and OCI-AML3 were incubated with DMSO or BKM120 (0.5–2 μM) for 24 h and the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) were assessed by the XF24 Flux Analyzer. BKM120 exposure profoundly affected the oxidative metabolism of both AML cell lines. Indeed, on the U-937, 24 h of treatment induced a clear dose-dependent decrease of the basal and maximal respiration (72.9% and 59.9% at 2 μM) as well of the mitochondrial ATP production (97.0%) when compared to their controls. Similarly, the OCR of OCI-AML3 cell line resulted decreased in a dose-dependent manner after exposure to BKM120 (Fig. 5, upper panels). In addition, BKM120 treatment was able to reduce the basal glycolysis (30.0% and 25.8% at 2 μM) and the glycolytic capacity (53.9% and 35.9%) of both AML cell models in a dose-dependent fashion (Fig. 5, lower panels). Bioenergetic perturbations promoted by BKM120 were then evaluated following 72 h of treatment on 2 primary samples (#4 and #16) which were characterized by different clinical features (chemo-resistant vs de novo AML). According to cell line results, all measured rates of the oxygen consumption (Fig. 6A) and of the glycolytic status (data not shown) in primary specimens were significantly (p < 0.05) reduced upon treatment with BKM120. Hence, these results demonstrate that metabolism alterations induced by BKM120 might contribute to the cytotoxicity of this compound.

BKM120 synergizes with DCA to enhance cytotoxicity in AML cell lines and primary samples. According to the metabolic importance of the PI3K pathway, we explored a novel therapeutic strategy combining BKM120 with DCA at doses around or below their IC50s on AML cell models and primary specimens. The U-937, HL-60 and KG-1 cell lines were exposed to increasing concentrations of BKM120 (0.5–1.5 μM) and DCA (1–3 mM) alone and in combination at a fixed ratio (1:2000) and cytotoxicity was monitored by FACS analysis up to 72 h. As shown in Fig. 7A, the combination of BKM120 and DCA was more effective in inhibiting cell growth and promoting massive apoptosis induction on all cell lines tested whereas single drugs did not. CIs were below 1 (range 0.2–0.6), thus indicating the strong synergistic interaction between these two drugs. Combined treatment was strikingly effective also on the DCA-resistant cell line, HL-60, increasing the percentage of apoptotic cells at 72 h from 17.6 ± 10.6 (BKM120 1.5 μM) and 14.3 ± 3.1 (DCA 3 mM) to 97.5 ± 0.1 (combination) (Supplementary Fig. S4A). BKM120/DCA combination was then assessed on 4 primary AML specimens, 3 de
Figure 4. BKM120 exerts pro-apoptotic activity on primary AML cells but not affects normal MNCs. (A) Effects on de novo primary AML samples incubated with the indicated concentrations of BKM120 up to 144 h. Data from each samples are shown as individual symbols on the figure. The horizontal grey lines and error bars represent mean values and SD, respectively. (B) Flow cytometry analysis of BKM120-induced apoptosis on the chemo-resistant AML sample #4 after 144 h of exposure. (C) Western blot analysis of three AML primary samples after 24 h of exposure to increasing concentrations of BKM120. Anti-GAPDH was used as loading control.

Figure 5. BKM120 modulates the metabolic phenotype of AML cell lines. Original Seahorse data adapted from Mito (upper panels) and GlycoStress tests (lower panels) on the indicated AML cell lines after 24 h of treatment with increasing concentrations of BKM120 or DMSO.
Figure 6. BKM120 affects the oxidative capabilities of primary AML samples. Original Seahorse data adapted from MitoStress tests on two primary AML cells after 72 h of treatment with increasing concentrations of BKM120 or DMSO.

Figure 7. Synergistic effects of BKM120 with DCA on AML cell lines and primary samples. (A) Effects on U-937 and KG-1 cell lines cultured with BKM120, DCA or their combination up to 72 h. Cell growth and apoptosis were evaluated by Trypan Blue exclusion and Annexin V/PI staining. Data are representative of one of multiple doses tested and are expressed as mean ± SD of three independent replicates. CI values are indicated for each cell line. (B) Effects on primary AML samples exposed to BKM120, DCA or their combination for 144 h. Data from de novo (circles) and chemo-resistant (triangle) samples are shown as individual symbols on the figure and represent one of multiple concentrations tested. The horizontal grey lines and error bars represent mean values and SD, respectively. CI values are reported for each patient. * for p < 0.05 compared to single drug treatments.
novo (#12, #13 and #17) and 1 chemo-resistant sample (#18), confirming its efficacy to decrease blast counts and induce apoptosis in a more pronounced way than single agents (Fig. 7B and Supplementary Fig. S4B).

BKM120 impairs AML tumor growth and prolongs survival in vivo. Cytotoxic efficacy of BKM120 was finally investigated in a xenotransplant mouse model of AML. NSG mice (n = 28) were intravenously injected with 1 × 10⁶ HL-60 cells and, one day after cell transfer, were randomized into two groups to receive 40 mg/kg of BKM120 or vehicle. BKM120 treatment markedly inhibited leukemia progression inducing a significant (p < 0.001) improvement of overall survival when compared to the control mice (Fig. 8A). Treatment was well tolerated as suggested by the maintenance of body weight and the lack of other signs of toxicity (data not shown). Thirty days after cell injection, AML-related symptoms were observed in the vehicle group (animals were hunchbacked and ruffled coat) and mice began to die. At necropsy, mice had enlarged spleen in comparison to BKM120-treated group (Fig. 8B). At day 45 after cell transfer, flow cytometry evaluation of the circulating human CD45⁺ cells in the murine PB was performed to assess AML engraftment showing that BKM120-treated mice carried significantly lower leukemia burden in the PB in comparison to the vehicle-treated group (Fig. 8C).

Discussion
It is well established that an aberrant expression of the PI3K/Akt/mTOR pathway plays a pivotal role in cancer cell proliferation, survival and chemotherapy resistance through the alteration of physiologic cell cycle progression, differentiation and growth. Over the last few years, several studies have shown the constitutive activation of this axis in different hematologic malignancies, including AML, providing the rationale for new targeted approaches. Furthermore, different groups have demonstrated that the PI3K/Akt/mTOR activation is an indicator of poor prognosis and chemoresistance in AML.

In the present study, we investigated for the first time the efficacy of the pan-class I PI3K inhibitor BKM120 as a potential therapeutic inhibitor of the PI3K/Akt/mTOR signaling network in AML. Previous reports in solid tumors and hematologic malignancies have shown that BKM120, alone or in combination with other drugs (e.g. standard chemotherapy or other small molecules), inhibits cell cycle progression and promotes apoptosis induction through the selective inhibition of the PI3K/Akt/mTOR pathway activity, thus supporting its potential clinical role in cancer. In the present study, we examined the in vitro cytotoxic potential of BKM120 on a wide panel of human AML cell lines characterized by different PI3K/Akt/mTOR pathway activation patterns. Our results demonstrate that BKM120 significantly reduced cell viability and triggered marked apoptosis induction in a dose- and time-dependent manner in all cell lines tested, regardless of their PI3K dependence. Accordingly to previous reports, BKM120-induced cytotoxicity in AML cell models was preceded by a temporary increase of cells in the G2/M phase of cell cycle, further supporting that BKM120 impairs cell cycle progression.
and mitosis regulation which ultimately turn into apoptosis. Clinical relevance of BKM120 was further confirmed on primary AML samples obtained from de novo and chemo-resistant patients with different PI3K/Akt/mTOR pathway activation and on MNCs obtained from healthy volunteers. BKM120 exposure was able to decrease the viability of leukemic blasts in a dose-dependent manner in all AML samples tested, de novo and chemo-resistant, resulting in a significant induction of apoptosis. The median IC_{50} was 1.52±μM, significantly lower than the maximum plasma concentration of BKM120 (4μM) obtained in a phase I clinical trial after administration of the maximum tolerated dose of this drug^{39}. By contrast, no considerable cytotoxicity was observed on resting and activated normal MNCs, thus suggesting the existence of a therapeutic window in humans. This evidence is further supported by the lack of relevant toxicity in patients with advanced leukemias treated with BKM120 in a phase I/II clinical trial^{40}. The efficacy of BKM120 in AML cells was strongly associated with the abrogation of the PI3K/Akt/mTOR signaling activity. As indicated by the densitometric analysis, BKM120 exposure dose-dependently reduced the phospho/total protein ratios of critical PI3K/Akt/mTOR pathway components, emphasizing once again the selective target inhibition prompted by this drug on cancer cells. We also documented a downregulation of mTORC1/2 phosphorylation levels as well as of the mTORC1 downstream targets, p70S6K and 4EBP1. These data are in agreement with previous reports^{27-29,36} showing the capacity of BKM120 at higher doses to inhibit also the catalytic activity of the mTOR kinase. Importantly, target inhibition was demonstrated on primary samples and was associated with a clear dephosphorylation of 4EBP1, a translational repressor involved in the synthesis of several oncogenic proteins^{41,42}.

Recently, it has been established that the PI3K/Akt/mTOR pathway strongly influences cellular metabolism through the direct regulation of Akt on metabolic enzymes and, indirectly, through the stimulation of mTORC1 activity^{43-45}. Moreover, the Akt activation status has been shown to mediate the metabolic effects in human leukemia cells^{46}. Therefore, we investigated whether BKM120 exposure could modulate the metabolic phenotype of AML cell lines and primary samples. In agreement with a recently published work on hepatocellular carcinoma^{27} we found that inhibition of the PI3K/Akt/mTOR signaling by BKM120 significantly reduced the basal and maximal respiration as well as the percentage of ATP synthesis from mitochondria in a dose-dependent manner when compared to their controls. Moreover, BKM120 exposure affects the glycolytic status of AML cells, decreasing both the basal glycolysis and the glycolytic capacity. These effects were clearly apparent on all tested AML cells, including primary samples, thus confirming that BKM120-induced modulation of altered metabolic fluxes in leukemic cells result into the induction of apoptosis.

Leukemic cells, like other cancer cells, are characterized by a reprogrammed glucose metabolism which provides energy and biosynthetic precursors or metabolic intermediates to sustain tumor needs^{47-49}. Altered glucose metabolism in AML has been shown to be closely associated with therapeutic resistance and clinical outcome^{46,47}, strongly contributing to the decreased sensitivity to some anti-leukemic agents such as arabinofuranosylcytidine (Ara-C). Conversely, inhibition of glycolysis suppressed AML cell proliferation and potentiated drug-induced cytotoxicity^{47}. Of note, Scotland et al.^{46} showed a striking correlation between PI3K/Akt/mTOR constitutive activation and susceptibility to glycolytic inhibitor. We thus decided to explore a novel therapeutic strategy combining DCA, a well-known metabolic modulator previously tested by us and other groups^{50,51}, also on AML cell lines, with BKM120 at doses around or below their IC_{50}. According to other reports showing the efficacy of simultaneous inhibition of Akt and glycolysis^{42}, we could demonstrate that BKM120/DCA combination synergistically inhibits cell lines proliferation and promotes apoptosis induction at significantly lower doses than single drugs. Importantly, the efficacy of the combination was also confirmed on both de novo and chemo-resistant primary samples, emphasizing the clinical relevance of targeted approaches simultaneously inhibiting altered signalling and the glycolitic pathway in AML cells. Finally, the evaluation of the in vivo potential of BKM120 on xenotransplant AML mouse models demonstrated that this compound efficiently inhibits cell engraftment, delays tumor development and prolongs the survival of AML-bearing mice without inducing any side effects or weight loss.

In conclusion, our pre-clinical results have documented that BKM120, as single agent or in combination with other drugs (i.e. glycolytic modulators), has a significant anti-leukemic activity towards AML cell lines and primary samples, thus supporting its clinical evaluation as a therapeutic agent for the management of AML.

Methods

Materials. BKM120, kindly provided by Novartis (Basel, Switzerland), was dissolved in dimethylsulphoxide (DMSO) to a stock concentration of 10mM for in vitro studies or prepared as described below for in vivo administration. DCA, a pyruvate dehydrogenase kinase inhibitor, was purchased from Sigma-Aldrich (St Louis, MO, USA). All other drugs (i.e. glycolytic modulators), has a significant anti-leukemic activity towards AML cell lines and primary samples. In agreement with a recently published work on hepatocellular carcinoma^{27} we found that inhibition of the PI3K/Akt/mTOR signaling by BKM120 significantly reduced the basal and maximal respiration as well as the percentage of ATP synthesis from mitochondria in a dose-dependent manner when compared to their controls. Moreover, BKM120 exposure affects the glycolytic status of AML cells, decreasing both the basal glycolysis and the glycolytic capacity. These effects were clearly apparent on all tested AML cells, including primary samples, thus confirming that BKM120-induced modulation of altered metabolic fluxes in leukemic cells result into the induction of apoptosis.

Leukemic cells, like other cancer cells, are characterized by a reprogrammed glucose metabolism which provides energy and biosynthetic precursors or metabolic intermediates to sustain tumor needs^{47-49}. Altered glucose metabolism in AML has been shown to be closely associated with therapeutic resistance and clinical outcome^{46,47}, strongly contributing to the decreased sensitivity to some anti-leukemic agents such as arabinofuranosylcytidine (Ara-C). Conversely, inhibition of glycolysis suppressed AML cell proliferation and potentiated drug-induced cytotoxicity^{47}. Of note, Scotland et al.^{46} showed a striking correlation between PI3K/Akt/mTOR constitutive activation and susceptibility to glycolytic inhibitor. We thus decided to explore a novel therapeutic strategy combining DCA, a well-known metabolic modulator previously tested by us and other groups^{50,51}, also on AML cell lines, with BKM120 at doses around or below their IC_{50}. According to other reports showing the efficacy of simultaneous inhibition of Akt and glycolysis^{42}, we could demonstrate that BKM120/DCA combination synergistically inhibits cell lines proliferation and promotes apoptosis induction at significantly lower doses than single drugs. Importantly, the efficacy of the combination was also confirmed on both de novo and chemo-resistant primary samples, emphasizing the clinical relevance of targeted approaches simultaneously inhibiting altered signalling and the glycolitic pathway in AML cells. Finally, the evaluation of the in vivo potential of BKM120 on xenotransplant AML mouse models demonstrated that this compound efficiently inhibits cell engraftment, delays tumor development and prolongs the survival of AML-bearing mice without inducing any side effects or weight loss.

In conclusion, our pre-clinical results have documented that BKM120, as single agent or in combination with other drugs (i.e. glycolytic modulators), has a significant anti-leukemic activity towards AML cell lines and primary samples, thus supporting its clinical evaluation as a therapeutic agent for the management of AML.

Materials. BKM120, kindly provided by Novartis (Basel, Switzerland), was dissolved in dimethylsulphoxide (DMSO) to a stock concentration of 10mM for in vitro studies or prepared as described below for in vivo administration. DCA, a pyruvate dehydrogenase kinase inhibitor, was purchased from Sigma-Aldrich (St Louis, MO, USA) and freshly diluted in Dulbeccos PBS just before each experiment.

For western blot analysis, the anti-GAPDH was obtained from Millipore Corporation (Billerica, MA, USA) while all other primary antibodies were bought from Cell Signaling Technology (Danvers, MA, USA). Secondary HRP-conjugated antibodies and x-ray films were purchased from GE Healthcare (Piscataway, NJ, USA). Electrochemiluminescence (ECL) reagent and non-fat dry milk were from Euroclone (Milan, Italy).

Cell culture and primary samples. The U-937, HL-60, HL-60Mx2, THP-1 and KG-1 cell lines were purchased from ATCC catalogue while the NB4, OCI-AML2, OCI-AML3 and MOLM13 were from DSMZ cell bank. All AML cell lines were grown at a concentration of 0.2 × 10⁶/mL in RPMI 1640 medium (Euroclone) supplemented with 10% fetal bovine serum, 2mM l-glutamine and 1% penicillin-streptomycin and maintained at 37°C and 5% CO₂. Primary samples from AML patients (n = 18) and mononuclear cells (MNCs) from healthy donors (n = 5) were collected after written informed consent from all subjects, purified by Lympholyte–H (Cedarlane, Ontario, Canada) density-gradient centrifugation and plated at a concentration of 1 × 10⁶/mL under the same culture conditions of cell lines. Experimental protocols were in accordance to the Helsinki Declaration and were approved by the Sapienza Institutional Review Board (Prot. #158/10 signed in February 18th, 2010). The characteristics of patients are reported in Supplementary Table S2.
Apoptosis and cell cycle analysis. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays (Sigma-Aldrich) were performed both to establish the optimal concentration range of drug treatment and to evaluate growth inhibitory effects on AML cell lines. Briefly, cells were seeded into 24-well plates and incubated for 72 h with increasing concentrations of BKM120 or with DMSO following which 100 μL of each condition were transferred in triplicate into a 96-well plate. Then, 10 μL of MTT were added to each well and plates were incubated for 3 h at 37 °C and 5% CO2. After 3 h, MTT was dissolved with 100 μL of solubilization solution and absorbance was measured at 570 nM with a LT-4000 spectrophotometer (Euroclone). All experiments were performed at least 3 times and results were expressed as mean ± standard deviation (SD).

Apoptosis induction was examined up to 72 h for AML cell lines and up to 144 h for primary AML samples using Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) staining, as previously described52. At the same time, cell cycle analyses were performed by acridine-orange (AO) technique, according to Tafuri et al.53. Flow cytometry data were collected by FACScan and Accuri C6 flow cytometers (BD Biosciences, CA, USA) and analyzed with the appropriate software.

Cell signaling and metabolic analysis. Cell lines and primary samples exposed to BKM120 were lysed in ice-solution containing 10 mM NaF, 1 mM Na3VO4, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 0.1% NaN3, 10 mM iodoacetamide, 3 mM PMSF and 1% Triton X-100 (Sigma-Aldrich) supplemented with protease inhibitor cocktail (Roche Diagnostic Corp, Indianapolis, IN, USA)54. Equal amounts of proteins were subjected to SDS–PAGE. After electrophoresis on nitrocellulose (Bio-Rad Laboratories, CA, USA), membranes were blocked in 5% non-fat dry milk and incubated overnight with primary antibodies, according to manufacturer’s instruction. Blots were then probed with HRP-conjugated secondary antibodies for 1 h at room temperature and developed using ECL reagent. Resulting signals were collected on x-ray films, digitally scanned and quantified using Image J software (NIH, Bethesda, MD, USA)54.

Bienergetic changes induced by drug treatment were evaluated using the XF24 Flux analyzer (Seahorse Biosciences, Billerica, MA, USA) which performs real-time measurements of OCR and ECAR directly on intact cells. Briefly, cell lines and primary samples were harvested from their cultures after 24 h and 72 h of treatment, respectively, washed twice in XF Base medium (Seahorse Biosciences) supplemented with 2 mM L-glutamine, 11 mM glucose and 1,2 mM pyruvate for MitoStress tests or with 2 mM L-glutamine for GlycoStress tests, and seeded in a 24-well XF test plate previously treated with 50 μg/mL poly-lysine (Sigma–Aldrich) at a density of 0.5 × 10^6/well and 1.5 × 10^6/well for cell lines and primary blasts, respectively. Each condition was plated at least in quadruplicate to minimize handling variations. XF Stress kits were purchased from Seahorse Biosciences and performed according to manufacturer’s instructions.

Mice and human leukemia transplants. Experiments were carried out on non-obese diabetic severe combined immunodeficient (NOD/SCID) interleukin-2 receptor g (IL-2Rg)–null (NSG) mice, 6 to 8-weeks-old. NSG mice were bred and housed under pathogen-free conditions in the animal facilities at the European Institute of Oncology–Italian Foundation for Cancer Research Institute of Molecular Oncology (IEO-IFOM, Milan, Italy). All animal experiments were carried out in strict accordance with the Italian laws (DLvo 26/2014 and following additions) and were approved by the institutional committee. For induction of acute leukemia, 1 × 10^6 HL-60 cells were injected intravenously through the lateral tail vein in non-irradiated mice. Human engraftment was defined by means of percentage of human cells in peripheral blood. BKM120 was prepared fresh daily just before HL-60 cells injection, mice were randomized in two groups: first group was treated daily for 40 days with BKM120 while the other was administered with vehicle as control. After HL-60 cells injection, mice were randomized in two groups: first group was treated daily for 40 days with BKM120 while the other was administered with vehicle as control.

In vivo flow cytometry analysis. Flow cytometry analyses were performed 45 days after transplant. Human cell engraftment in the peripheral blood was investigated after mechanical dissociation of the organs. The phenotype of human cells in NSG mice was evaluated using the following anti-human antibodies: anti-CD15-FITC (80H5), -CD13-PeCy7 (IMMU 103.44), -CD45-APC (J.33), -CD33-APC-Cy7 (D3HL60.251) from Beckman Coulter (Irvings, TX, USA) and anti-mouse CD45-PE (30-F11) from BD Biosciences to exclude murine cells contamination. Cell suspensions were evaluated by a FACSCalibur (BD Biosciences) using analysis gates designed to exclude dead cells, platelets and debris. Percentages of stained cells were determined and compared to appropriate negative controls. Seven-amoinoactinomycin D (7AAD) from Sigma–Aldrich was used to enumerate viable, apoptotic and dead cells.

Data analysis and statistics. For all in vitro results, at least three independent experiments were performed to determine mean and SD values. IC50 was calculated using the CalcuSyn software (Biosoft, Cambridge, MA) based on the number of live cells at 72 h. For combination experiments, synergism, additive effects, and antagonism were assessed using the Chou–Talalay method and the CalcuSyn software. CI values of 1 were considered as additive, < 1 as synergistic and > 1 antagonistic.

For in vivo study the sample size has been established by the calculator for sample size requirement for log rank test in survival analysis (https://www.statsdirect.com/SSizSurvival_Pgm.php) setting the probability of type I error (α) at 0.05, the power (1–β) at 0.80, and the minimum difference to be found significant at 60%. The size required to highlight such a difference has been found at least at 14 animals per cohort. Statistical comparisons were performed using the two-sided paired Student’s t-test, analysis of variance (ANOVA) and linear regression when data were normally distributed or the non-parametric analyses of Spearman and Mann–Whitney when data were not normally distributed. Values of p < 0.05 were considered as statistically significant.

References

1. Ferrara, F. & Schiffer, C. A. Acute myeloid leukemia in adults. Lancet 381(9865), 484–95 (2013).
2. Park, S. et al. Haematologica 95(5), 819–828 (2010).
3. Scholl, C., Gilliland, D. G. & Fröhling, S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 35(4), 336–45 (2008).
4. Suhreit, P. et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106(3), 1063–5 (2005).
5. Xu, Q., Simpson, S. E., Scialla, T. J., Bagg, A. & Carroll, M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102(3), 972–80 (2003).
6. Engeljman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8), 550–62 (2009).
7. Vanhaesebroeck, B., Guillermot-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5), 329–41 (2010).
8. Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41), 5497–510 (2008).
9. Chan, C. H. et al. Posttranslational regulation of Akt in human cancer. Cell Biosci 4(1), 59 (2014).
10. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712), 1098–101 (2005).
11. Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149(2), 274-93274–293 (2012).
12. Fruman, D. A. & Rummel, C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13(2), 140–56 (2014).
13. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol-3-kinase/AKT pathway in human cancer. Nat Rev Cancer 2(7), 489–501 (2002).
14. Gallay, N. et al. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23(6), 1029–38 (2009).
15. Grandage, V. L., Gale, R. E., Linch, D. C. & Khwaja, A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κappaB, Mapkinase and p53 pathways. Leukemia 19(4), 586–94 (2005).
16. Min, Y. H. et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukaemia: its significance as a prognostic variable. Leukemia 17(5), 995–7 (2003).
17. Brandts, C. H. et al. Constitutive activation of Akt by PI3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 65(21), 9643–50 (2005).
18. Kornblau, S. M. et al. Functional proteinomic profiling of AML predicts response and survival. Blood 113(1), 154–64 (2009).
19. Martelli, A. M., Evangelisti, C., Chiarini, P. & McCubrey, J. A. The phosphorylation and activation of PI3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1(2), 89–103 (2010).
20. Rodon, J., Dienstmann, R., Serra, V. & Tabernero, J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10(3), 143–53 (2013).
21. Martelli, A. M. et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 25(7), 1064–79 (2011).
22. Burger, M. T. et al. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett 2(10), 774–9 (2011).
23. Maia, S. M. et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11(2), 317–28 (2012).
24. Brachmann, S. M. et al. Characterization of the mechanism of action of the pan class I PI3 inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther 11(8), 1747–57 (2012).
25. Jane, E. et al. Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes APT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells. J Pharmacol Exp Ther 350(1), 22–35 (2014).
26. Reux, B. N. et al. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res 16(1), R9 (2014).
27. Kirstein, M. M. et al. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. Liver Int 33(5), 780–93 (2013).
28. Ren, H. et al. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Lett 328(2), 139–46 (2012).
29. Koul, D. et al. Antitumor activity of NVP-BKM120—a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18(1), 184–95 (2012).
30. Ibrahim, Y. et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2(11), 1036–47 (2012).
31. Zheng, Y. et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myelo-monocytic activity with dexamethasone. J Mol Med (609), 695–706 (2012).
32. Zang, C. et al. Inhibition of pan-class I phosphatidylinositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. Leuk Lymphoma 55(2), 425–34 (2014).
33. Rosich, L. et al. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica 98(11), 1739–47 (2013).
34. Amrein, L., Shawi, M., Grenier, J., Aloyz, R. & Panasci, L. The phosphatidylinositol-3-kinase kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. Int J Cancer 133(1), 247–52 (2013).
35. Lonetti, A. et al. Activity of the pan-class I phosphoinositide-3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia 26(6), 1196–206 (2014).
36. Mueller, A. et al. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 69(6), 1601–15 (2012).
37. Polak, R. & Buitenhuis, M. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 119(4), 911–23 (2012).
38. Martelli, A. M. et al. Phosphoinositide-3-kinase/Akt signaling pathway and its therapeutic implications for human acute myeloid leukemia. Leukemia 20(6), 911–28 (2006).
39. Bendell, J. C. et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3), 282–90 (2012).
40. Daven, N. et al. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I/II trial of patients with advanced leukemias. Haematologica 99(Suppl 1), 1–796 (abstract P188) (2014).
41. Evangelisti, C. et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 25(5), 781–91 (2011).
42. Willems, L. et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 26(6), 1195–202 (2012).
43. Ward, P. S. & Thompson, C. B. Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol 4(7), a006783 (2012).
44. Braccini, I. et al. PI3K keeps the balance between metabolism and cancer. Adv Biol Regul 52(3), 389–405 (2012).
45. Mosca, E. et al. Systems biology of the metabolic network regulated by the Akt pathway. Biotechnol Adv 30(1), 131–41 (2012).
46. Scotland, S. et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia 27(11), 2129–38 (2013).
47. Chen, W. L. et al. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood 124(10), 1645–54 (2014).
48. Herst, P. M., Howman, R. A., Neeson, P. J., Berridge, M. V. & Ritchie, D. S. The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. J Leukoc Biol 89(1), 51–5 (2011).
49. DePerardinis, R., L. J., Lun, J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7(1), 11–20 (2008).
50. Mirabili, S. et al. Modulation of glycolytic metabolism by dichloroacetate induces apoptosis in acute myeloid leukemia cells. Haematologica 99 (suppl 2), S1–S13 (abstract PO-059) (2014).
51. DeSalvo, J. et al. Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia. Mol Cancer Res 10(7), 969–78 (2012).
52. Ricciardi, M. R. et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 19(9), 1543–9 (2005).
53. Tafuri, A. & Andreef, M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4(12), 826–34 (1990).
54. Ricciardi, M. R. et al. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies. J Mol Med (Berl) 90(10), 1133–44 (2012).

Acknowledgements
The authors would like to thank Novartis for providing NVP-BKM120, RomaAIL (Associazione Italiana contro le Leucemie-linfomi e mieloma) for laboratory spaces and David Calef for helping with language editing. This work was supported by grants from Sapienza University (C26G13WSNF and C26A137XXS), MIUR (PRIN 2010 AXJ2J7_003) and Fondazione Internazionale D’AMATO Onlus.

Author Contributions
M.A. designed and performed the research, analyzed data and wrote the manuscript; M.R.R. designed the research, analyzed data and edited the manuscript; S.M. performed metabolic experiments; R.L. performed functional assays; S.O., F.R. and G.T. performed in vivo experiments; R.F. provided clinical samples; F.B. designed in vivo research and edited the manuscript; S.A. conceived of the research, provided clinical samples and edited the manuscript; A.T. conceived the research and edited the manuscript. All authors reviewed and approved the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Allegretti, M. et al. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Sci. Rep. 5, 18137; doi: 10.1038/srep18137 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Erratum: The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia

Matteo Allegretti, Maria Rosaria Ricciardi, Roberto Licchetta, Simone Mirabili, Stefania Orecchioni, Francesca Reggiani, Giovanna Talarico, Roberto Foà, Francesco Bertolini, Sergio Amadori, Maria Rosaria Torrisi & Agostino Tafuri

Scientific Reports 5:18137; doi: 10.1038/srep18137; published online 17 December 2015; updated on 05 February 2016

This Article contains errors in the Author Contributions Statement.

“M.A. designed and performed the research, analyzed data and wrote the manuscript; M.R.R. designed the research, analyzed data and edited the manuscript; S.M. performed metabolic experiments; R.L. performed functional assays; S.O., F.R. and G.T. performed in vivo experiments; R.F. provided clinical samples; F.B. designed in vivo research and edited the manuscript; S.A. conceived of the research, provided clinical samples and edited the manuscript; M.R.T. edited the manuscript; A.T. conceived the research and edited the manuscript. All authors reviewed and approved the manuscript.”

should read:

“M.A. designed and performed the research, analyzed data and wrote the manuscript; M.R.R. designed the research, analyzed data and edited the manuscript; R.L. performed functional assay; S.M. performed metabolic experiments; S.O., F.R. and G.T. performed in vivo experiments; R.F. provided clinical samples; F.B. designed in vivo research and edited the manuscript; S.A. conceived of the research, provided clinical samples and edited the manuscript; M.R.T. edited the manuscript; A.T. conceived the research and edited the manuscript. All authors reviewed and approved the manuscript.”

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/